ALHC
BEARISH
$19.22
Live
Alignment Healthcare, Inc. · NASDAQ
Target $25.42
(+32.2%)
$11.62
52W Range
$23.87
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 28, 2026
Market cap
$3.85B
P/E
N/A
ROE
-0.7%
Profit margin
-0.0%
Debt/Equity
1.84
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ALHC's Advanced Deterministic Scorecard reveals significant financial health concerns, with a Piotroski F-Score of 2/9 indicating weak operational and financial stability. The absence of an Altman Z-Score and the company's high debt/equity ratio of 1.84 raise distress risk concerns, especially given negative profitability metrics and a lack of positive cash flow indicators. Despite strong revenue growth (44.4% YoY) and impressive earnings surprises in recent quarters, the company remains unprofitable with negative ROE (-0.70%) and ROA (1.00%), undermining long-term sustainability. Insider selling totaling $454.78M over six months signals strong bearish sentiment from leadership, further eroding confidence. The stock trades at a premium valuation (Price/Book: 21.89) despite poor profitability, suggesting overvaluation relative to fundamentals.
Key Strengths
Strong revenue growth of 44.4% YoY, indicating market expansion and execution capability
Exceptional earnings surprise history with average 458.81% beat in last 4 quarters
Positive recent EPS growth (Q/Q: +42.9%, YoY: +171.4%) signaling improving profitability trajectory
High analyst target price of $25.42 implies strong growth optimism despite current losses
Gross margin of 12.37% suggests some pricing power and cost control in operations
Key Risks
Piotroski F-Score of 2/9 indicates severe financial distress signals and weak operational efficiency
Negative ROE (-0.70%) and ROA (1.00%) reflect poor capital utilization and unprofitability
Debt/Equity ratio of 1.84 is high, especially for a loss-making company with no clear path to profitability
Insider selling of $454.78M in 6 months signals lack of confidence from leadership
No available cash flow or dividend data, suggesting potential liquidity strain and no return to shareholders
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
36
Weak
30
75
55
20
0
AI Verdict
Weak
Key drivers: Low Piotroski F-Score (2/9), Negative profitability and ROE, High debt/equity ratio, Massive insider selling, Premium valuation without earnings support
Confidence
88%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 0.97 is below 1.0, suggesting potential undervaluation on revenue basis
- Forward P/E of 26.79 is below sector average (197.76), indicating relative valuation appeal
Watchpoints
- No Graham Number or intrinsic value available due to negative earnings
- Price/Book of 21.89 is extremely high for a loss-making company
- No free cash flow or operating cash flow data to support valuation
Future
75/100
Ref Growth rates
Positives
- 44.4% YoY revenue growth is exceptional in healthcare sector
- Recent EPS growth (Q/Q +42.9%, YoY +171.4%) shows accelerating profitability
- High earnings surprise average (458.81%) suggests strong execution and upside potential
Watchpoints
- Forward P/E of 26.79 is high for a company with no current earnings
- No clear path to sustained profitability despite growth
- High growth may be unsustainable without margin improvement
Past
55/100
Ref Historical trends
Positives
- Consistent earnings beat in last 4 quarters (3/4), with large positive surprises
- Improving trend in EPS from -0.18 to -0.05 over 6 quarters
- Positive Q/Q EPS growth of +42.9% indicates momentum
Watchpoints
- Persistent losses across 21 quarters, with multiple negative surprises
- Negative ROE and ROA indicate poor capital efficiency over time
- Historical profitability remains weak despite growth
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.71 and quick ratio of 1.54 suggest short-term liquidity adequacy
- Gross margin of 12.37% is positive and stable
Watchpoints
- Piotroski F-Score of 2/9 is extremely low, indicating severe financial distress
- No Altman Z-Score available, but debt/equity of 1.84 is high for a non-profitable firm
- Negative ROE and ROA signal poor capital allocation and operational inefficiency
- No available cash flow data raises liquidity concerns
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio available
- Dividend Strength score of 0/100 confirms no dividend policy
- Negative earnings make dividend sustainability impossible
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$19.22
Analyst Target
$25.42
Upside/Downside
+32.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ALHC and closest competitors.
Updated 2026-02-27
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ALHC
Alignment Healthcare, Inc.
Primary
|
+11.0% | +93.4% | +42.7% | +17.5% | -12.9% | -6.7% |
|
TWST
Twist Bioscience Corporation
Peer
|
-53.5% | +355.4% | +81.2% | +87.5% | +40.7% | +9.1% |
|
INDV
Indivior Pharmaceuticals, Inc.
Peer
|
+218.1% | +75.0% | +241.6% | +28.4% | -7.0% | +0.2% |
|
TMDX
TransMedics Group, Inc.
Peer
|
+298.9% | +27.5% | +29.0% | -5.7% | -0.7% | -0.2% |
|
NAMS
NewAmsterdam Pharma Company N.V.
Peer
|
+246.8% | +157.0% | +109.7% | -9.0% | +15.6% | +1.6% |
ALH
Alignment Healthcare, Inc.
Primary
5Y
+11.0%
3Y
+93.4%
1Y
+42.7%
6M
+17.5%
1M
-12.9%
1W
-6.7%
TWS
Twist Bioscience Corporation
Peer
5Y
-53.5%
3Y
+355.4%
1Y
+81.2%
6M
+87.5%
1M
+40.7%
1W
+9.1%
IND
Indivior Pharmaceuticals, Inc.
Peer
5Y
+218.1%
3Y
+75.0%
1Y
+241.6%
6M
+28.4%
1M
-7.0%
1W
+0.2%
TMD
TransMedics Group, Inc.
Peer
5Y
+298.9%
3Y
+27.5%
1Y
+29.0%
6M
-5.7%
1M
-0.7%
1W
-0.2%
NAM
NewAmsterdam Pharma Company N.V.
Peer
5Y
+246.8%
3Y
+157.0%
1Y
+109.7%
6M
-9.0%
1M
+15.6%
1W
+1.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
26.79
PEG Ratio
N/A
P/B Ratio
21.89
P/S Ratio
0.97
EV/Revenue
0.92
EV/EBITDA
80.67
Market Cap
$3.85B
Profitability
Profit margins and return metrics
Profit Margin
-0.02%
Operating Margin
-1.01%
Gross Margin
12.37%
ROE
-0.7%
ROA
1.0%
Growth
Revenue and earnings growth rates
Revenue Growth
+44.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.84
High debt
Current Ratio
1.71
Good
Quick Ratio
1.54
Excellent
Cash/Share
$2.96
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-26
$N/A
+98.2% surprise
2025-10-30
$0.1
+1081.0% surprise
2025-07-30
$0.07
+197.2% surprise
Healthcare Sector Comparison
Comparing ALHC against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-0.7%
This Stock
vs
-88.14%
Sector Avg
-99.2%
(Below Avg)
Profit Margin
-0.02%
This Stock
vs
-16.28%
Sector Avg
-99.9%
(Weaker)
Debt to Equity
1.84
This Stock
vs
2.66
Sector Avg
-30.9%
(Less Debt)
Revenue Growth
44.4%
This Stock
vs
124.04%
Sector Avg
-64.2%
(Slower)
Current Ratio
1.71
This Stock
vs
4.47
Sector Avg
-61.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ALHC
Alignment Healthcare, Inc.
|
BEARISH | $3.85B | - | -0.7% | -0.0% | $19.22 | |
|
TWST
Twist Bioscience Corporation
|
BEARISH | $3.84B | - | -16.8% | -19.6% | $62.61 | Compare |
|
INDV
Indivior Pharmaceuticals, Inc.
|
NEUTRAL | $3.82B | 18.62 | -% | 16.9% | $30.54 | Compare |
|
TMDX
TransMedics Group, Inc.
|
BULLISH | $3.91B | 23.28 | 54.2% | 31.4% | $113.13 | Compare |
|
NAMS
NewAmsterdam Pharma Company N.V.
|
BEARISH | $3.96B | - | -28.3% | -% | $34.44 | Compare |
ALHC
Alignment...
BEARISH
Mkt Cap
$3.8B
P/E
-
ROE
-0.7%
Price
$19.22
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-23 | MANSOUR ADNAN R | Officer | Stock Award | 23,441 | - |
| 2026-02-17 | MARONEY DAWN CHRISTINE | President | Sale | 30,000 | $618,990 |
| 2026-02-10 | KAO JOHN E | Chief Executive Officer | Sale | 180,000 | $3,687,354 |
| 2026-02-10 | WAGNER ANDREAS P | Officer | Sale | 22,238 | $455,212 |
| 2026-01-15 | MARONEY DAWN CHRISTINE | President | Sale | 30,000 | $674,451 |
| 2026-01-12 | KAO JOHN E | Chief Executive Officer | Sale | 180,000 | $3,799,219 |
| 2026-01-06 | KIM HYONG J | Officer | Sale | 16,506 | $352,357 |
| 2026-01-06 | MARONEY DAWN CHRISTINE | President | Sale | 328,152 | $6,871,050 |
| 2026-01-02 | JOYCE CHRISTOPHER J | Officer | Sale | 10,611 | $212,590 |
| 2025-12-29 | JOYCE CHRISTOPHER J | Officer | Sale | 16,187 | $303,388 |
| 2025-12-29 | KAO JOHN E | Chief Executive Officer | Sale | 605,648 | $11,351,467 |
| 2025-12-29 | KIM HYONG J | Officer | Sale | 12,694 | $237,920 |
| 2025-12-29 | MARONEY DAWN CHRISTINE | President | Sale | 282,070 | $5,286,747 |
| 2025-12-29 | SCAVO ROBERT L | Chief Technology Officer | Sale | 69,541 | $1,303,384 |
| 2025-12-15 | MARONEY DAWN CHRISTINE | President | Sale | 130,000 | $2,601,111 |
MANSOUR ADNAN R
Officer
2026-02-23
23,441 shares
MARONEY DAWN CHRISTINE
President
2026-02-17
30,000 shares
·
$618,990
KAO JOHN E
Chief Executive Officer
2026-02-10
180,000 shares
·
$3,687,354
WAGNER ANDREAS P
Officer
2026-02-10
22,238 shares
·
$455,212
MARONEY DAWN CHRISTINE
President
2026-01-15
30,000 shares
·
$674,451
KAO JOHN E
Chief Executive Officer
2026-01-12
180,000 shares
·
$3,799,219
KIM HYONG J
Officer
2026-01-06
16,506 shares
·
$352,357
MARONEY DAWN CHRISTINE
President
2026-01-06
328,152 shares
·
$6,871,050
JOYCE CHRISTOPHER J
Officer
2026-01-02
10,611 shares
·
$212,590
JOYCE CHRISTOPHER J
Officer
2025-12-29
16,187 shares
·
$303,388
KAO JOHN E
Chief Executive Officer
2025-12-29
605,648 shares
·
$11,351,467
KIM HYONG J
Officer
2025-12-29
12,694 shares
·
$237,920
MARONEY DAWN CHRISTINE
President
2025-12-29
282,070 shares
·
$5,286,747
SCAVO ROBERT L
Chief Technology Officer
2025-12-29
69,541 shares
·
$1,303,384
MARONEY DAWN CHRISTINE
President
2025-12-15
130,000 shares
·
$2,601,111
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
12 analysts
JP Morgan
2026-02-05
Overweight
Overweight
TD Cowen
2026-01-16
Buy
Buy
UBS
2026-01-14
Neutral
Neutral
Piper Sandler
2026-01-06
Overweight
Overweight
JP Morgan
2025-12-17
Overweight
Overweight
JP Morgan
2025-11-24
Neutral
Overweight
JP Morgan
2025-11-05
Neutral
Neutral
Barclays
2025-11-03
Equal-Weight
Equal-Weight
UBS
2025-10-31
Neutral
Neutral
Goldman Sachs
2025-10-14
Buy
Past News Coverage
Recent headlines mentioning ALHC from our newsroom.
Newest → oldest
No matching news yet.